• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Inogen Inc

    3/27/26 9:55:41 AM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 10)


    Inogen Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    45780L104

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    45780L104


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Inogen Inc
    (b)Address of issuer's principal executive offices:

    301 Coromar Drive, Goleta, CA, 93117
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/27/2026
    Get the next $INGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    6/16/2025$14.00Buy
    B. Riley Securities
    5/22/2025$12.00Hold → Buy
    Needham
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    More analyst ratings

    $INGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Inogen Inc

    SCHEDULE 13G/A - Inogen Inc (0001294133) (Subject)

    3/27/26 9:55:41 AM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Inogen Inc

    S-8 - Inogen Inc (0001294133) (Filer)

    2/27/26 4:33:26 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Inogen Inc

    10-K - Inogen Inc (0001294133) (Filer)

    2/27/26 4:12:23 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:42:36 PM ET
    $INGN
    Industrial Specialties
    Health Care

    CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:41:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chief Accounting Officer Wright Mary E was granted 2,851 shares, converted options into 7,506 shares and covered exercise/tax liability with 3,408 shares, increasing direct ownership by 57% to 19,129 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/3/26 5:00:25 PM ET
    $INGN
    Industrial Specialties
    Health Care

    EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M converted options into 25,017 shares, covered exercise/tax liability with 15,382 shares and was granted 3,603 shares, increasing direct ownership by 98% to 26,747 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/3/26 4:59:20 PM ET
    $INGN
    Industrial Specialties
    Health Care

    EVP, Bus Dev, GC & Sec Smith Kevin P. converted options into 14,005 shares, covered exercise/tax liability with 6,276 shares and was granted 1,500 shares, increasing direct ownership by 72% to 22,007 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/3/26 4:57:51 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 17, 2026 at 3:00 p.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-p

    3/5/26 9:15:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook

    Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

    2/24/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces $30 Million Share Repurchase Program

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has authorized a share repurchase program for up to $30 million of its outstanding common stock. "This authorization reflects our confidence in Inogen's strategy, progress towards profitability goals, and long-term growth trajectory," said Kevin Smith, President and Chief Executive Officer. "With a strong, debt-free balance sheet, we view this program as providing additional flexibility to deploy capital to support continued investment in innovation and portfolio expansion while enhancing shareholder value." The r

    2/24/26 4:00:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Inogen with a new price target

    B. Riley Securities initiated coverage of Inogen with a rating of Buy and set a new price target of $14.00

    6/16/25 7:50:27 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by Needham with a new price target

    Needham upgraded Inogen from Hold to Buy and set a new price target of $12.00

    5/22/25 8:16:14 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by William Blair

    William Blair upgraded Inogen from Mkt Perform to Outperform

    2/15/24 6:28:38 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer

    Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. "Naga's deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership," said Kevin Smith, President and Chief Executive Officer of Inogen, "His ability to integrate software, data, and devices to improve user experiences will be instrume

    9/25/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

    11/7/24 4:04:00 PM ET
    $INGN
    $SGHT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $INGN
    Financials

    Live finance-specific insights

    View All

    Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook

    Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

    2/24/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025

    Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%. For the full year 2025, the Com

    1/12/26 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Third Quarter 2025 Financial Results

    Delivered seventh consecutive quarter of mid-single-digit revenue growth Reiterating full-year revenue guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2025. Recent Highlights $92.4 million revenue, a year-over-year increase of 4.0%, marking the seventh consecutive quarter of mid-single-digit percentage growth GAAP net loss of $5.3 million and adjusted net loss of $0.5 million compared to prior year GAAP net loss of $6.0 million and adjusted net loss of $2.6 million $2.3 million adjusted EBITDA, the third consecutive quart

    11/5/25 7:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inogen Inc

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    11/14/24 11:12:09 AM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Inogen Inc

    SC 13G - Inogen Inc (0001294133) (Subject)

    4/23/24 8:25:34 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Inogen Inc (Amendment)

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    2/14/24 4:00:17 PM ET
    $INGN
    Industrial Specialties
    Health Care